Azitromicina, un macrólido diferente: perfil terapéutico en infecciones odontogénicas

Herrera Ustariz, Iván.
Rev. Fundac. Juan Jose Carraro ; 11(23): 9-13, sept.-oct. 2006. tab
Artigo em Espanhol | LILACS | ID: lil-447244

Documentos relacionados

  1. Azithromycin, a potent autophagy inhibitor for cancer therapy, perturbs cytoskeletal protein dynamics.
  2. [Long-term macrolide therapy in asthma].
  3. Efficacy of azithromycin in treating Ureaplasma urealyticum: a systematic review and meta-analysis.
  4. Mechanism of action, resistance, synergism, and clinical implications of azithromycin.
  5. A multicenter retrospective electronic health record database evaluation of subjects with Mycoplasma genitalium.
  6. Antibody Responses to Two Recombinant Treponemal Antigens (rp17 and TmpA) before and after Azithromycin Treatment for Yaws in Ghana and Papua New Guinea.
  7. The role of rifampicin within the treatment of <i>Mycobacterium avium</i> pulmonary disease.
  8. Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant Shigella sonnei Infections in a Retirement Community-Vermont, 2018.
  9. Azithromycin in viral infections.
  10. Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact.